Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 4/20 | 0.40 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735712 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL18588484 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL24506182 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL21716640 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL21716641 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL24503494 | 0.83 | ALDH1A1 (0.44) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL24334194 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TAAR1NPSR1FPR3FPR2 | |
| SCHEMBL25139918 | 0.79 | TAAR1 (0.40) | ALDH1A1TAAR1FPR3FPR2POLB | |
| SCHEMBL25139914 | 0.79 | TAAR1 (0.40) | ALDH1A1TAAR1FPR3FPR2POLB | |
| SCHEMBL26506517 | 0.77 | ALDH1A1 (0.40) | ALDH1A1TAAR1NPSR1FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | ALDH1A1 239/4885TAAR1 2346/4885NPSR1 1893/4885 |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | ALDH1A1 4509/4885TAAR1 3316/4885NPSR1 548/4885 |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | ALDH1A1 4398/4885TAAR1 2537/4885NPSR1 663/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | ALDH1A1 140/4885TAAR1 1442/4885NPSR1 354/4885 |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | ALDH1A1 4398/4885TAAR1 2537/4885NPSR1 663/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | ALDH1A1 631/4885TAAR1 2602/4885NPSR1 1570/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | ALDH1A1 143/4885TAAR1 1420/4885NPSR1 355/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | ALDH1A1 4398/4885TAAR1 2537/4885NPSR1 663/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ALDH1A1 1053/4885TAAR1 2768/4885NPSR1 1363/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | ALDH1A1 4509/4885TAAR1 3316/4885NPSR1 548/4885 |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | GHRHR, GHSR, GCG | ALDH1A1 4509/4885TAAR1 3316/4885NPSR1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.